The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.

ScinoPharm receives US FDA approval for glatiramer acetate injection to treat multiple sclerosis: Taiwan Tuesday, January 6, 2026, 14:00 Hrs [IST] ScinoPharm Taiwan, a professiona ...

Taiwanese drugmaker ScinoPharm (TWSE: 1789) has secured approval from the US Food and Drug Administration for its glatiramer ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris VTRS.O and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.

About 400,000 Americans have multiple sclerosis, and up until now, the only drugs offered to them to slow the course of the disease had to be injected or dripped into a vein. But soon, it seems, they ...

NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's Copaxone reduced the risk of patients developing multiple sclerosis after they showed an initial sign of the central nervous system ...

Copaxone (glatiramer acetate injection) has potential interactions with other medications. These interactions could cause harmful effects. Copaxone is used in adults to treat relapsing forms of ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...